Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies

BACKGROUND: There is limited clinical trial and/or real-world evidence comparing differences among currently approved fixed-dose combination (FDC) long-acting muscarinic antagonist (LAMA)/long-acting beta2-agonist (LABA) treatments. OBJECTIVE: To compare chronic obstructive pulmonary disease (COPD)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Palli, Swetha R, Xie, Bin, Chastek, Benjamin, Elliott, Caitlin A, Bengtson, Lindsay G S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394199/
https://www.ncbi.nlm.nih.gov/pubmed/33764161
http://dx.doi.org/10.18553/jmcp.2021.20514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394199/
https://www.ncbi.nlm.nih.gov/pubmed/33764161
http://dx.doi.org/10.18553/jmcp.2021.20514

Ejemplares similares